-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiff Oncology Q3 net loss narrows 21% to $8.86 million

PUBT·11/12/2026 12:14:14
Cardiff Oncology Q3 net loss narrows 21% to $8.86 million
  • Cardiff Oncology’s third-quarter 2026 net loss narrowed 21% year over year to $8.86 million.
  • Royalty revenues rose 43% to $171,000, while operating expenses fell 22% to $9.39 million from a year earlier.
  • Cash resources totaled $33.8 million at September 30, 2026, sufficient to fund operations through the third quarter of 2027.
  • Median progression-free survival remains unreached for the proposed Phase 3 onvansertib regimen, versus approximately 11 months for combined standard-of-care arms.
  • The registrational Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer could start in the first quarter of 2027, subject to financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120700PRIMZONEFULLFEED9876018) on November 12, 2026, and is solely responsible for the information contained therein.